Clinical Studies

The study has firmly established a potentially important role for VAL201 in treating hormone induced refractory prostate cancer and other conditions of hormone induced uncontrolled cell growth including breast and ovarian cancer, among others – conditions which currently have high medical needs.

ValiFinn will conduct the management of certain aspects of VAL201 late preclinical work and will assist on the regulatory work pertaining to the clinical trials and will manage certain aspects of the clinical work regarding hormone induced refractory cancer.

Information on ValiFinn:- Please visit http://www.valifinn.com for all the current clinical biomarker and diagnostic services offered.